Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Assets (2021 - 2025)

ARS Pharmaceuticals' Non-Current Assets history spans 5 years, with the latest figure at $42.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 153.62% year-over-year to $42.8 million; the TTM value through Dec 2025 reached $132.2 million, up 368.09%, while the annual FY2025 figure was $42.8 million, 153.62% up from the prior year.
  • Non-Current Assets for Q4 2025 was $42.8 million at ARS Pharmaceuticals, up from $33.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $51.1 million in Q1 2022 and bottomed at $265000.0 in Q3 2022.
  • The 5-year median for Non-Current Assets is $4.0 million (2021), against an average of $15.8 million.
  • The largest annual shift saw Non-Current Assets plummeted 99.44% in 2022 before it surged 2508.79% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $716000.0 in 2021, then skyrocketed by 421.65% to $3.7 million in 2022, then tumbled by 60.86% to $1.5 million in 2023, then skyrocketed by 1053.08% to $16.9 million in 2024, then skyrocketed by 153.62% to $42.8 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Non-Current Assets are $42.8 million (Q4 2025), $33.9 million (Q3 2025), and $32.0 million (Q2 2025).